Robuta

https://stockhouse.com/companies/ratios?symbol=acrs NDAQ:ACRS | Company Fundamentals | Aclaris Therapeutics Inc Explore key ratios, efficiency ratios, dividends, and other fundamentals for Aclaris Therapeutics Inc (NDAQ:ACRS). Use concise and easy to view charts and... company fundamentalsndaqacrsaclaristherapeutics https://www.biospace.com/aclaris-announces-proposed-public-offering-of-common-stock-jan-19-2021 Aclaris Announces Proposed Public Offering of Common Stock - Jan 19, 2021 - BioSpace Jan 20, 2021 - Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, announced... jan 19 2021public offering https://www.benzinga.com/analyst-ratings/upgrades/21/04/20726346/benzingas-top-ratings-upgrades-downgrades-for-april-21-2021 Benzinga's Top Ratings Upgrades, Downgrades For April 21, 2021 - Aclaris Therapeutics... https://www.nasdaq.com/market-activity/stocks/acrs/institutional-holdings Aclaris Therapeutics, Inc. Common Stock (ACRS) Institutional Holdings | Nasdaq Find the latest institutional holdings data for Aclaris Therapeutics, Inc. Common Stock (ACRS) including shareholders, ownership summaries, and holding... common stockinstitutional holdingsaclaristherapeuticsinc https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-acrs/aclaris-therapeutics/news/is-aclaris-therapeutics-nasdaqacrs-in-a-good-position-to-del Is Aclaris Therapeutics (NASDAQ:ACRS) In A Good Position To Deliver On Growth Plans? - Simply Wall... Just because a business does not make any money, does not mean that the stock will go down. For example, although... https://stockhouse.com/companies/peers?symbol=acrs NDAQ:ACRS | Peers Comparison | Aclaris Therapeutics Inc Get fundamentals and stock price comparisons of industry peers of Aclaris Therapeutics Inc (NDAQ:ACRS). Presented in easy to view graphs and tables. ndaqacrspeerscomparisonaclaris https://stockhouse.com/companies/filings?symbol=acrs NDAQ:ACRS | Corporate Filings | Aclaris Therapeutics Inc Search and view corporate filing documents, including annual reports, for Aclaris Therapeutics Inc (NDAQ:ACRS). Pulled from SEDAR and SEC filings. corporate filingsndaqacrsaclaristherapeutics https://investingnews.com/aclaris-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-and-clinical-update/ Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and... May 7, 2026 - - Full Top Line Results from Phase 1a SAD/MAD Trial of ATI-052 Exceed Aclaris' Target Profile, Validating Potential Best-in-Class Potency Advantage and... first quarter 2026financial resultsaclaristherapeuticsreports https://www.prnewswire.com/news-releases/acrs-loss-notice-rosen-a-leading-law-firm-reminds-aclaris-therapeutics-inc-investors-of-important-september-30th-deadline-in-securities-class-action--acrs-300923558.html ACRS LOSS NOTICE: ROSEN, A LEADING LAW FIRM, Reminds Aclaris Therapeutics, Inc. Investors of... /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aclaris Therapeutics, Inc. from May 8, 2018... https://www.macrotrends.net/stocks/charts/ACRS/aclaris-therapeutics/gross-profit Aclaris Therapeutics Gross Profit 2014-2026 | ACRS | MacroTrends Aclaris Therapeutics gross profit from 2014 to 2026. Gross profit can be defined as the profit a company makes after deducting the variable costs directly... gross profitaclaristherapeutics20142026 https://www.fiercebiotech.com/biotech/aclaris-limps-out-to-a-55m-ipo-as-biotech-falters-on-wall-street Aclaris limps out to a $55M IPO as biotech falters on Wall Street | Fierce Biotech Oct 7, 2015 - Dermatology drug developer Aclaris Therapeutics priced its IPO well below its expected range, raising $55 million as a prolonged bear turn has dampened Wall... https://stockhouse.com/companies/insiders?symbol=acrs NDAQ:ACRS | Insider Transactions | Aclaris Therapeutics Inc See what company insiders are buying and selling at Aclaris Therapeutics Inc (NDAQ:ACRS). Use this to inform yourself about what officers and directors may be... insider transactionsndaqacrsaclaristherapeutics https://www.biospace.com/aclaris-therapeutics-announces-publication-of-preclinical-research-of-zunsemetinib-in-pancreatic-cancer-in-science-translational-medicine Aclaris Therapeutics Announces Publication of Preclinical Research of Zunsemetinib in Pancreatic... Dec 3, 2021 - Aclaris Therapeutics, Inc. today announced the publication of preclinical research of zunsemetinib in pancreatic cancer in the peer-reviewed journal Science... preclinical researchaclaristherapeuticsannouncespublication https://www.biospace.com/press-releases/aclaris-therapeutics-secures-u-s-food-and-drug-administration-ind-clearance-for-ati-052-enabling-advancement-of-its-novel-bispecific-anti-tslp-il-4r-investigational-antibody Aclaris Therapeutics Secures U.S. Food and Drug Administration IND Clearance for ATI-052, Enabling... https://www.sec.gov/Archives/edgar/data/1557746/000110465926020540/acrs-20251231x10k.htm Aclaris Therapeutics, Inc._December 31, 2025 december 31aclaristherapeuticsinc2025 https://www.annualreports.com/Company/aclaris-therapeutics-inc Aclaris Therapeutics, Inc. - AnnualReports.com aclaristherapeuticsinc